Hemostasis and bleeding disorders

Last updated: July 4, 2023

Summarytoggle arrow icon

Bleeding disorders are a group of heterogeneous conditions characterized by defects in hemostasis that lead to an increased susceptibility to bleeding (also known as hemorrhagic diathesis). They are classified into disorders of primary hemostasis (when caused by a platelet abnormality), disorders of secondary hemostasis (when caused by defects in the extrinsic and/or intrinsic pathway of the coagulation cascade), and hyperfibrinolysis (when there is increased clot degradation). Although clinical features may overlap, mucocutaneous bleeding (e.g., epistaxis, petechiae, gastrointestinal bleeding) is associated with disorders of primary hemostasis, and bleeding into potential spaces (e.g., hemarthrosis, muscular bleeding) is characteristic of disorders of secondary hemostasis. The diagnostic workup of a bleeding disorder begins with a detailed clinical assessment, the CBC, and a coagulation panel. This typically allows the disorder to be classified as one of primary or secondary hemostasis. Specialized studies are then required to determine the specific etiology so that treatment can be initiated. Treatment may include transfusion of blood products, replacement of specific coagulation factors, or administration of adjuvant medications (e.g., tranexamic acid or desmopressin).

Hemostasistoggle arrow icon

Overview [1][2]

Hemostasis is the physiological process by which a bleeding stops. Its final result is a thrombus (blood clot), which consists of blood cells and fibrin strands. Hemostasis involves the following mechanisms:

Primary hemostasis

Secondary hemostasis

Overview of coagulation factors
Factor number Descriptive name Activated by Involvement in pathways Function
Common Intrinsic Extrinsic


  • Proaccelerin
  • Proconvertin
  • Factor XIa
  • Complexes TF-VIIa and VIIIa-IXa
  • Stabilizes the fibrin network by introducing crosslinks

* = preferred term [3]
= rarely used term

The coagulation cascade requires the presence of calcium ions (factor IV).

A helpful way of remembering the coagulation factors of the extrinsic pathway is 3 + 7 = 10: Tissue factor (factor III) and factor VII form a complex that activates factor X of the common pathway.
A helpful way of remembering the coagulation factors of the common pathway is 10/5 = 2 × 1: Factors Xa and Va form a complex that cleaves prothrombin (factor II) to thrombin (IIa). Factor IIa then cleaves fibrinogen (I) into insoluble fibrin monomers (Ia).

Inhibition of hemostasis

In order to prevent hypercoagulability as well as excessive bleeding, activation of the coagulation cascade and the processes that inhibit it occur simultaneously in the circulatory system (procoagulant-anticoagulant balance).

Diseases that affect the inhibitors of the coagulation cascade may lead to hypercoagulability.

Fibrinolysistoggle arrow icon

Overview [2]

Fibrinolytic therapy [4]

Alteplase is a synthetic tissue plasminogen activator that converts plasminogen to plasmin. It is used in the treatment of STEMI, massive pulmonary embolism, and ischemic stroke.

Disorders of fibrinolysis

Hypoplasminogenemia [7]

Etiologytoggle arrow icon

Hemorrhagic diathesis is the abnormally increased susceptibility to bleeding.

Disorders of primary hemostasis

Disorders of secondary hemostasis (disorders of the coagulation cascade)

In disorders of primary hemostasis, platelet aggregation is impaired, whereas in disorders of secondary hemostasis it is the coagulation cascade that is impaired.

Hyperfibrinolysis [12]


  • Definition: abnormally low fibrinolytic activity, resulting in thrombosis
  • Etiology
    • tPA or uPA deficiency
    • Overexpression of PAI-1 or TAFI

Hypofibrinogenemia [13]

Clinical featurestoggle arrow icon

Clinical features of bleeding disorders [15][16]

Disorder Characteristics of bleeding Manifestations

Primary hemostasis disorders [9]

  • Onset: immediately after trauma
Secondary hemostasis disorders
  • Onset: delayed (minutes to hours after trauma)
Disseminated intravascular coagulation
  • Variable (depends on underlying cause)
  • Bleeding symptoms may include:
  • Symptoms of hypercoagulation (see “Clinical features” in “DIC”)

Superficial, petechial bleeding indicates defects of primary hemostasis, whereas large, palpable ecchymoses and deep tissue bleeding suggest defects of secondary hemostasis!

Diagnosticstoggle arrow icon

Clinical assessment and basic laboratory testing are used to differentiate between primary and secondary disorders of hemostasis. Advanced testing is used to identify the specific disorder.

Clinical assessment [17][18][19]

Most bleeding disorders are acquired; i.e., secondary to medications or associated with acute or chronic illness. [17]

Women presenting with menorrhagia should also be evaluated by a gynecologist.

Bleeding assessment tools (BATs) [20][21][22]

BATs are questionnaires that standardize the assessment of bleeding symptoms and identify patients who may benefit from advanced testing. Multiple tools are available.

Initial laboratory studies [18][19][20][27]

Von Willebrand disease is the most common inherited bleeding disorder, affecting up to 1% of the population. Von Willebrand factor concentration and vWF activity are now commonly part of initial diagnostic studies. [20][27]

Interpretation of laboratory findings in bleeding disorders [18][20][28]

Defective pathway Disorders

Platelet count

PFA or bleeding time

Disorders of primary hemostasis


  • Normal
  • Normal

Platelet dysfunction (e.g., aspirin therapy. chronic kidney disease)

  • Normal
  • Normal
  • Normal
Disorders of secondary hemostasis

Extrinsic pathway (e.g., factor VII deficiency)

  • Normal
  • Normal
  • Normal

Intrinsic pathway (e.g., hemophilia, heparin therapy)

  • Normal
  • Normal
  • Normal

Intrinsic and extrinsic pathways (e.g., deficiency of vitamin K-dependent coagulation factors)

  • Normal
  • Normal
Disorders of primary AND secondary hemostasis

Von Willebrand disease

  • Normal
  • Normal
  • Normal/↑ [27]

Disseminated intravascular coagulation (DIC)

DIC is characterized by thrombosis, hemorrhage, and organ dysfunction and can be a medical emergency that requires immediate treatment.

A detailed clinical assessment and initial laboratory studies are sufficient to diagnose the most common disorders of hemostasis (e.g., platelet dysfunction secondary to medications or bleeding disorders associated with acute or chronic disease).

Advanced laboratory studies [18][19]

Advanced laboratory studies help identify specific disorders. The choice of studies depends on the suspected underlying pathology and usually requires specialist consult.

Suspected disorders of primary hemostasis

Suspected disorders of secondary hemostasis [19][30]

  • Congenital factor deficiencies: confirmed with factor assays (low factor concentrations)
  • Presence of factor inhibitors: can be diagnosed using mixing studies
Possible mechanisms and coagulation factors affected in disorders of secondary hemostasis [19][30]
Elevated PT/INR Normal PT/INR
Elevated aPTT
Normal aPTT
  • See “Disorder unclear after initial testing” below

Disorder unclear after initial testing [19]

Additional testing is required if suspicion of a bleeding disorder is high but coagulation testing is normal. Possible etiologies include:

If the diagnosis remains unclear, repeat testing for vWD is recommended. [19]

Treatmenttoggle arrow icon

Treatment should be guided by a specialist and target the specific cause of the bleeding. Occasionally, the transfusion of blood products may be indicated. For patients with acute or major bleeding, see “Management of acute bleeding” below.

General principles [30][32]

  • Avoid medications that may impair hemostasis.
  • Ensure optimal preventive medical and dental health care.
  • Consult a specialist to determine any preventive measures that are necessary before invasive procedures.
  • Provide patient education on lifestyle modification in the setting of bleeding disorders.
  • Consider screening for HIV and hepatitis if the patient has a history of multiple transfusions.

Disorders of primary hemostasis [33][34]

Platelet transfusion

Disease-specific treatment

One random donor platelet unit typically increases platelet count by 5,000–10,000/mm3 in a 70-kg patient. One apheresis unit (the equivalent of 6–8 single units) increases platelet count by 30,000–40,000/mm3. [37]

Disorders of secondary hemostasis

Inherited coagulation factor deficiency [27]

Acquired coagulation factor deficiency

The effect of liver disease on hemostasis is complex: The clinical effects of thrombocytopenia and reduced coagulation factor synthesis are often negated by a simultaneous decrease in the production of profibrinolytic factors. Bleeding often does not occur, even if the laboratory values of hemostasis are markedly abnormal. [39]

Impaired coagulation factor function

Patients with an inhibitor to a coagulation factor are at high risk of severe or fatal bleeding. [43]

Management of acute bleedingtoggle arrow icon

Management [17]

Diagnostics should not delay factor replacement therapy in patients with known bleeding disorders presenting with major bleeding. [47][48][49]

Patients with a suspected disorder of secondary hemostasis presenting with major bleeding can benefit from the transfusion of fresh frozen plasma while diagnostic studies are performed. [17]

Diagnostics [17]

Referencestoggle arrow icon

  1. Girolami A, Luzzatto G, Varvarikis C, Pellati D, Sartori R, Girolami B. Main clinical manifestations of a bleeding diathesis: an often disregarded aspect of medical and surgical history taking. Haemophilia. 2005; 11 (3): p.193-202.doi: 10.1111/j.1365-2516.2005.01100.x . | Open in Read by QxMD
  2. Drews RE. Approach to the adult patient with a bleeding diathesis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: January 11, 2017. Accessed: February 8, 2017.
  3. Overview of Platelet Disorders. Updated: September 1, 2014. Accessed: February 8, 2017.
  4. Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Elsevier Health Sciences ; 2018
  5. Neutze D, Roque J. Clinical Evaluation of Bleeding and Bruising in Primary Care. Am Fam Physician. 2016; 93 (4): p.279-86.
  6. Boender J, Kruip MJHA, Leebeek FWG. A diagnostic approach to mild bleeding disorders. J of Thromb and Haemost. 2016; 14 (8): p.1507-1516.doi: 10.1111/jth.13368 . | Open in Read by QxMD
  7. Rodeghiero F, Pabinger I, Ragni M, et al. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. Hemasphere. 2019; 3 (5).doi: 10.1097/hs9.0000000000000286 . | Open in Read by QxMD
  8. RODEGHIERO F, TOSETTO A, ABSHIRE T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J of Thromb and Haemost. 2010; 8 (9): p.2063-2065.doi: 10.1111/j.1538-7836.2010.03975.x . | Open in Read by QxMD
  9. Adler M, Kaufmann J, Alberio L, Nagler M. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. J Thromb Haemost. 2019; 17 (7): p.1104-1112.doi: 10.1111/jth.14454 . | Open in Read by QxMD
  10. Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014; 20 (6): p.831-835.doi: 10.1111/hae.12503 . | Open in Read by QxMD
  11. Moenen FCJI, Nelemans PJ, Schols SEM, Schouten HC, Henskens YMC, Beckers EAM. The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review. Haemophilia. 2018; 24 (4): p.525-535.doi: 10.1111/hae.13486 . | Open in Read by QxMD
  12. Fasulo MR, Biguzzi E, Abbattista M, et al. The ISTH Bleeding Assessment Tool and the risk of future bleeding. Journal of Thrombosis and Haemostasis. 2017; 16 (1): p.125-130.doi: 10.1111/jth.13883 . | Open in Read by QxMD
  13. Lowe GC, Lordkipanidzé M, Watson SP. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. Journal of Thrombosis and Haemostasis. 2013; 11 (9): p.1663-1668.doi: 10.1111/jth.12332 . | Open in Read by QxMD
  14. James PD, Goodeve AC. von Willebrand disease. Genet Med. 2011; 13 (5): p.365-376.doi: 10.1097/gim.0b013e3182035931 . | Open in Read by QxMD
  15. Bashawri LA, Ahmed MA. The approach to a patient with a bleeding disorder: for the primary care physician.. Journal of family & community medicine. 2007; 14 (2): p.53-8.
  16. Paniccia R, Priora R, Alessandrello Liotta A, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015: p.133.doi: 10.2147/vhrm.s44469 . | Open in Read by QxMD
  17. Kruse-Jarres R, Singleton TC, Leissinger CA. Identification and basic management of bleeding disorders in adults.. J Am Board Fam Med. 2014; 27 (4): p.549-64.doi: 10.3122/jabfm.2014.04.130227 . | Open in Read by QxMD
  18. Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haem. 2018; 16 (4): p.652-662.doi: 10.1111/jth.13957 . | Open in Read by QxMD
  19. Drebes A, de Vos M, Gill S, et al. Prothrombin Complex Concentrates for Coagulopathy in Liver Disease: Single‐Center, Clinical Experience in 105 Patients. Hepatology Communications. 2019.doi: 10.1002/hep4.1293 . | Open in Read by QxMD
  20. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Critical Care. 2011; 15 (1): p.201.doi: 10.1186/cc9311 . | Open in Read by QxMD
  21. Schulman S, Furie B. How I treat poisoning with vitamin K antagonists. Blood. 2015; 125 (3): p.438-442.doi: 10.1182/blood-2014-08-597781 . | Open in Read by QxMD
  22. Obaji S, Alikhan R, Rayment R, Carter P, Macartney N, Collins P. Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia. 2015; 22 (2): p.285-291.doi: 10.1111/hae.12811 . | Open in Read by QxMD
  23. Savage SA, Sumislawski JJ, Zarzaur BL, Dutton WP, Croce MA, Fabian TC. The new metric to define large-volume hemorrhage. Journal of Trauma and Acute Care Surgery. 2015; 78 (2): p.224-230.doi: 10.1097/ta.0000000000000502 . | Open in Read by QxMD
  24. The National Blood Authority’s Patient Blood Management Guideline: Module 1 – Critical Bleeding/Massive Transfusion. Updated: January 1, 2011. Accessed: February 17, 2021.
  25. Guidelines for Emergency Department Management of individuals with hemophilia and other bleeding disorders. Updated: December 5, 2019. Accessed: April 22, 2021.
  26. Müller MC, Meijers JC, Vroom MB, et al. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care. 2014; 18 (1): p.R30.doi: 10.1186/cc13721 . | Open in Read by QxMD
  27. Müller MCA, Meijers JC, van Meenen DM, Thachil J, et al. Thromboelastometry in critically ill patients with disseminated intravascular coagulation.. Blood Coagul Fibrinolysis. 2019; 30 (5): p.181-187.doi: 10.1097/MBC.0000000000000808 . | Open in Read by QxMD
  28. Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding. Br J Haematol. 2018; 182 (6): p.789-806.doi: 10.1111/bjh.15524 . | Open in Read by QxMD
  29. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess (Rockv). 2015; 19 (58): p.1-228.doi: 10.3310/hta19580 . | Open in Read by QxMD
  30. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017; 72 (4): p.519-531.doi: 10.1111/anae.13765 . | Open in Read by QxMD
  31. Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – A systematic review and meta-analysis. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2017; 25 (1).doi: 10.1186/s13049-017-0378-9 . | Open in Read by QxMD
  32. Whiting D, DiNardo JA. TEG and ROTEM: Technology and clinical applications. Am J Hematol. 2014; 89 (2): p.228-232.doi: 10.1002/ajh.23599 . | Open in Read by QxMD
  33. Leung LLK, Mannucci PM, Tirnauer JS. Overview of Hemostasis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: December 15, 2016. Accessed: August 29, 2017.
  34. Hall JE. Guyton and Hall Textbook of Medical Physiology. Elsevier ; 2016
  35. Giangrande PLF. Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors. Br J Haematol. 2003; 121 (5): p.703-712.doi: 10.1046/j.1365-2141.2003.04333.x . | Open in Read by QxMD
  36. Rydz N, James P. Approach to the Diagnosis and Management of Common Bleeding Disorders. Semin Thromb Hemost. 2012; 38 (07): p.711-719.doi: 10.1055/s-0032-1326783 . | Open in Read by QxMD
  37. Konkle BA. Acquired Disorders of Platelet Function. Hematology Am Soc Hematol Educ Program. 2011; 2011 (1): p.391-396.doi: 10.1182/asheducation-2011.1.391 . | Open in Read by QxMD
  38. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction.. Am J Hematol. 1990; 33 (1): p.39-45.doi: 10.1002/ajh.2830330108 . | Open in Read by QxMD
  39. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007; 3 (3): p.138-153.doi: 10.1038/ncpneph0421 . | Open in Read by QxMD
  40. Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.. Drug Saf. 2008; 31 (3): p.217-30.doi: 10.2165/00002018-200831030-00003 . | Open in Read by QxMD
  41. Mohanty D. Current concepts in platelet transfusion. Asian Journal of Transfusion Science. 2009; 3 (1): p.18.doi: 10.4103/0973-6247.45257 . | Open in Read by QxMD
  42. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology. 2006; 44 (4): p.1039-1046.doi: 10.1002/hep.21303 . | Open in Read by QxMD
  43. Hunt BJ. Bleeding and Coagulopathies in Critical Care. N Engl J Med. 2014; 370 (9): p.847-859.doi: 10.1056/nejmra1208626 . | Open in Read by QxMD
  44. Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Research and Practice in Thrombosis and Haemostasis. 2017; 1 (2): p.150-161.doi: 10.1002/rth2.12028 . | Open in Read by QxMD
  45. Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology. 2015; 2015 (1): p.243-249.doi: 10.1182/asheducation-2015.1.243 . | Open in Read by QxMD
  46. W Collins P, Chalmers E, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013; 162 (6): p.758-773.doi: 10.1111/bjh.12463 . | Open in Read by QxMD
  47. Katzung B,Trevor A. Basic and Clinical Pharmacology. McGraw-Hill Education ; 2014
  48. Marder VJ, Novokhatny V.. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.. Journal of Thrombosis and Haemostasis. 2010.
  49. Nazari J, Davison R, Kaplan K, Fintel D. Adverse Reactions to Thrombolytic Agents. Med Toxicol. 1987; 2 (4): p.274-286.doi: 10.1007/bf03259869 . | Open in Read by QxMD
  50. Hypoplasminogenemia. Updated: September 1, 2021. Accessed: October 22, 2021.
  51. RYPLAZIM® (plasminogen, human-tvmh). . Accessed: October 22, 2021.
  52. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998; 66 (6): p.2145-2152.doi: 10.1016/s0003-4975(98)00749-8 . | Open in Read by QxMD
  53. Franchini M, Castaman G, Coppola A, et al. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015; 13 (3): p.498-513.doi: 10.2450/2015.0141-15 . | Open in Read by QxMD
  54. Fay WP, Leung LLK, Tirnauer JS. Thrombotic and Hemorrhagic Disorders due to Abnormal Fibrinolysis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: May 26, 2017. Accessed: August 28, 2017.
  55. Thompson RJ, Portmann BC, Roberts EA. Genetic and metabolic liver disease. Elsevier ; 2011: p. 157-259
  56. Shaz BH, MD BH, Hillyer CD, MD CD, Gil MR. Transfusion Medicine and Hemostasis. Elsevier Science ; 2019: p. 1050

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer